Cynapsus Therapeutics, Inc. (OTC MKTS: CYNAF) is a specialty pharmaceutical company developing sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease. The company’s leading drug candidate, APL-130277, is an easy-to-use, fast-acting formulation of apomorphine, which is the only drug approved in the United States to rescue patients from OFF episodes. The company is completing pivotal studies in advance of submitting a new drug application in 2016. For more information, visit the company’s website at www.cynapsus.ca.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.